article Open AccessTop 1% cited

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Journal of Clinical Oncology · 2010 · Vol. 28(19) · pp. 3167–3175

Julie R. Brahmer✉(Johns Hopkins University)Charles G. Drake(Johns Hopkins University)Ira Wollner(Johns Hopkins University)John D. Powderly(Johns Hopkins University)Joel Picus(Johns Hopkins University)William H. Sharfman(Johns Hopkins University)Elizabeth Stankevich(Johns Hopkins University)Alice Pons(Johns Hopkins University)Theresa M. Salay(Johns Hopkins University)Tracee L. McMiller(Johns Hopkins University)Marta M. Gilson(Johns Hopkins University)Changyu Wang(Johns Hopkins University)Mark Selby(Johns Hopkins University)Janis M. Taube(Johns Hopkins University)Robert A. Anders(Johns Hopkins University)Lieping Chen(Johns Hopkins University)Alan J. Korman(Johns Hopkins University)Drew M. Pardoll(Johns Hopkins University)Israel Lowy(Johns Hopkins University)Suzanne L. Topalian(Johns Hopkins University)

View via DOI Full-text PDF

Abstract

Blocking the PD-1 immune checkpoint with intermittent antibody dosing is well tolerated and associated with evidence of antitumor activity. Exploration of alternative dosing regimens and combinatorial therapies with vaccines, targeted therapies, and/or other checkpoint inhibitors is warranted.

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Immunotherapy and Immune ResponsesMedicinePharmacodynamicsTolerabilityNivolumabMelanomaInternal medicineAdverse effectRenal cell carcinomaCancerResponse Evaluation Criteria in Solid Tumors

MeSH terms

NivolumabAdultAgedAged, 80 and overAntibodies, MonoclonalCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellDose-Response Relationship, DrugFatigueFemaleHumansKidney NeoplasmsLung NeoplasmsLymphopeniaMale

Citations

2,913

FWCI

69.96

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape